Chemotherapy in Hodgkin lymphoma (Hodgkin disease) in University Hospital Würzburg
University Hospital Würzburg
Würzburg, Germany
{"translation_price":"50","translation_doc_price":"40","child_coefficient":"1.1","transfer_price":"2.00","transfer_price_vip":"5.00","constant_transfer_price_vip":350,"constant_transfer_price":150,"constant_transfer_distanse":60,"type":"treatment","program_full_story":"<ul>\n\t<li>Initial presentation in the clinic<\/li>\n\t<li>clinical history taking<\/li>\n\t<li>review of medical records<\/li>\n\t<li>physical examination<\/li>\n\t<li>laboratory tests:\n\t<ul>\n\t\t<li>complete blood count<\/li>\n\t\t<li>general urine analysis<\/li>\n\t\t<li>biochemical analysis of blood<\/li>\n\t\t<li>TSH-basal, fT3, fT4<\/li>\n\t\t<li>tumor markers<\/li>\n\t\t<li>inflammation indicators<\/li>\n\t\t<li>indicators of blood coagulation<\/li>\n\t<\/ul>\n\t<\/li>\n\t<li>ultrasound scan<\/li>\n\t<li>CT \/ MRI scan<\/li>\n\t<li>1 course of chemotherapy <\/li>\n\t<li>control examinations<\/li>\n\t<li>nursing services<\/li>\n\t<li>consultations of related specialists<\/li>\n\t<li>explanation of individual treatment plan<\/li>\n<\/ul>\n<div class=\"program_how_program_going mt-4\"><h4>How program is carried out<\/h4><p style=\"text-align:justify\"><strong>During the first visit<\/strong>, the doctor will conduct a clinical examination and go through the results of previous laboratory tests and instrumental examinations. After that, you will undergo an additional examination, including laboratory assessment of liver and kidney function, ultrasound scan. Based on the received results, the doctor will elaborate the chemotherapy regimen. If necessary, related medical specialists will be involved in the elaboration of a treatment regimen (tumor board).<\/p>\n\n<p style=\"text-align:justify\"><strong>Chemotherapy <\/strong>is carried out as the day hospital procedure, without mandatory admission to the hospital. After the placement of a venous catheter, you will stay in a comfortable ward. An infusion system will be connected to the catheter, through which the required drug or a drug combination will be administered. All drugs are administered by intravenous drip, slowly, so the total duration of the infusion can be up to several hours. All this time, doctors and nurses will monitor your health condition closely.<\/p>\n\n<p style=\"text-align:justify\"><strong>After the course of chemotherapy<\/strong>, you will stay under medical supervision in the ward for a few more hours. If your general condition is good, your doctor will allow you to leave the hospital. You will receive the medical report with detailed recommendations regarding further treatment. In the future, you will be able to have a distant consultation with your attending physician and schedule the next course of chemotherapy, if necessary.<\/p>\n<\/div><div class=\"program_required_documents mt-4\"><h4>Required documents<\/h4><ul>\n\t<li style=\"text-align: justify;\">Medical records<\/li>\n\t<li style=\"text-align: justify;\">MRI\/CT scan, PET scan (if available)<\/li>\n<\/ul>\n<\/div>","program_full_story_crm":"<ul>\n\t<li>Initial presentation in the clinic<\/li>\n\t<li>clinical history taking<\/li>\n\t<li>review of medical records<\/li>\n\t<li>physical examination<\/li>\n\t<li>laboratory tests:\n\t<ul>\n\t\t<li>complete blood count<\/li>\n\t\t<li>general urine analysis<\/li>\n\t\t<li>biochemical analysis of blood<\/li>\n\t\t<li>TSH-basal, fT3, fT4<\/li>\n\t\t<li>tumor markers<\/li>\n\t\t<li>inflammation indicators<\/li>\n\t\t<li>indicators of blood coagulation<\/li>\n\t<\/ul>\n\t<\/li>\n\t<li>ultrasound scan<\/li>\n\t<li>CT \/ MRI scan<\/li>\n\t<li>1 course of chemotherapy <\/li>\n\t<li>control examinations<\/li>\n\t<li>nursing services<\/li>\n\t<li>consultations of related specialists<\/li>\n\t<li>explanation of individual treatment plan<\/li>\n<\/ul>\n<div class=\"program_how_program_going mt-4\"><h4>How program is carried out<\/h4><p style=\"text-align:justify\"><strong>During the first visit<\/strong>, the doctor will conduct a clinical examination and go through the results of previous laboratory tests and instrumental examinations. After that, you will undergo an additional examination, including laboratory assessment of liver and kidney function, ultrasound scan. Based on the received results, the doctor will elaborate the chemotherapy regimen. If necessary, related medical specialists will be involved in the elaboration of a treatment regimen (tumor board).<\/p>\n\n<p style=\"text-align:justify\"><strong>Chemotherapy <\/strong>is carried out as the day hospital procedure, without mandatory admission to the hospital. After the placement of a venous catheter, you will stay in a comfortable ward. An infusion system will be connected to the catheter, through which the required drug or a drug combination will be administered. All drugs are administered by intravenous drip, slowly, so the total duration of the infusion can be up to several hours. All this time, doctors and nurses will monitor your health condition closely.<\/p>\n\n<p style=\"text-align:justify\"><strong>After the course of chemotherapy<\/strong>, you will stay under medical supervision in the ward for a few more hours. If your general condition is good, your doctor will allow you to leave the hospital. You will receive the medical report with detailed recommendations regarding further treatment. In the future, you will be able to have a distant consultation with your attending physician and schedule the next course of chemotherapy, if necessary.<\/p>\n<\/div>","is_ambulant":"1","bh_fee":"0","only_for_children":"0","no_service":"0","with_prepayment":"1","show_calculator":"1","paket_type":"1","btn_type":"2","clinic_icon":"5ff71d14a2f75.jpg","city":"W\u00fcrzburg","clinic_site":"www.ukw.de","department_recommend":"1","country":"Germany","country_id":"1","clinic_name":"University Hospital W\u00fcrzburg","cinic_name":"University Hospital W\u00fcrzburg","department_id":"1295","duration":"5","direction":"Hematology","min_duration":0,"clinic_id":"831","paketPrice":3200,"paket":"<ul>\n <li> Interpreter up to 8 hours<\/li>\n <li>Translation of up to 5 pages<\/li>\n <li>Visa support<\/li>\n\n<\/ul>","title":"Chemotherapy in Hodgkin lymphoma (Hodgkin disease)","price":{"val":7603.59,"type":"val"},"price_surcharge":0,"price_surcharge_clear":0,"extra_service_clinic":[],"extra_service":[],"translation_hours":"0","translation_doc_count":null,"roads":[{"id":"27","distance":"102","airport_title":"N\u00fcrnberg"},{"id":"6","distance":"126","airport_title":"Frankfurt a.M."},{"id":"19","distance":"167","airport_title":"Stuttgart"}],"pakets":[],"lang":{"day":"Day","days":"days","ambulatory":"Outpatient","stationaryProgram":"Inpatient"}}
Program id #
226105
Prof. Dr. med. Hermann Einsele
Department of Gastroenterology, Hematology, Oncology, Hepatology, Infectology, Rheumatology and Clinical Immunology
Specialized in: gastroenterology, hematology, oncology, hepatology, infectology, rheumatology, clinical immunology The program includes:
- Initial presentation in the clinic
- clinical history taking
- review of medical records
- physical examination
- laboratory tests:
- complete blood count
- general urine analysis
- biochemical analysis of blood
- TSH-basal, fT3, fT4
- tumor markers
- inflammation indicators
- indicators of blood coagulation
- ultrasound scan
- CT / MRI scan
- 1 course of chemotherapy
- control examinations
- nursing services
- consultations of related specialists
- explanation of individual treatment plan
How program is carried out
During the first visit, the doctor will conduct a clinical examination and go through the results of previous laboratory tests and instrumental examinations. After that, you will undergo an additional examination, including laboratory assessment of liver and kidney function, ultrasound scan. Based on the received results, the doctor will elaborate the chemotherapy regimen. If necessary, related medical specialists will be involved in the elaboration of a treatment regimen (tumor board).
Chemotherapy is carried out as the day hospital procedure, without mandatory admission to the hospital. After the placement of a venous catheter, you will stay in a comfortable ward. An infusion system will be connected to the catheter, through which the required drug or a drug combination will be administered. All drugs are administered by intravenous drip, slowly, so the total duration of the infusion can be up to several hours. All this time, doctors and nurses will monitor your health condition closely.
After the course of chemotherapy, you will stay under medical supervision in the ward for a few more hours. If your general condition is good, your doctor will allow you to leave the hospital. You will receive the medical report with detailed recommendations regarding further treatment. In the future, you will be able to have a distant consultation with your attending physician and schedule the next course of chemotherapy, if necessary.
Required documents
- Medical records
- MRI/CT scan, PET scan (if available)
Service
Price from:
Type of program :
Price for 1 day:
Expected duration of the program:
The minimum duration of the program:
Select
You may also book:
Hospital directly:
Saving:
BookingHealth Price from:
About the department
The Department of Gastroenterology, Hematology, Oncology, Hepatology, Infectology, Rheumatology and Clinical Immunology at the university Hospital Würzburg offers the full range of diagnostics and treatment in these fields. The department specializes in the treatment of benign and malignant diseases of the digestive system, liver and bile ducts, the hematopoietic system, etc. Much attention is paid to the interdisciplinary cooperation (Cancer Center Mainfranken, etc.). The Chief Physician of the department is Prof. Dr. med. Hermann Einsele.
The gastroenterological spectrum of the department includes the diagnostics and treatment of all diseases of the digestive organs (esophagus, stomach, small and large intestine, liver, bile ducts and pancreas). The team of the department has a unique experience in the treatment of chronic inflammatory bowel diseases, oncological diseases of the gastrointestinal tract, biliary tract and pancreas. In addition, the department ranks among the leading Centers for Neuroendocrine Tumors in Germany.
In the field of hematology, the department offers the diagnostics and treatment of the entire spectrum of diseases of the blood, hematopoietic and lymphatic systems. The department specializes in the treatment of benign (various types of anemia, thrombocytopenia, neutropenia, accumulation diseases, etc.) and malignant (acute and chronic forms of leukemia, malignant lymphomas, multiple myeloma, plasmacytoma, myelodysplastic syndrome, etc.) diseases. The malignancies are treated within the framework of the Comprehensive Cancer Center Mainfranken.
Another department’s focus is hepatology. It provides a competent care for the patients with all acute and chronic diseases of the liver and biliary tract. In particular, the department specializes in the treatment of patients with impaired liver function, as well as with liver and biliary tract tumors. The patients with rare (often hereditary) liver diseases are treated in collaboration with the Center for Rare Diseases of Northern Bavaria.
The service range of the department includes the following options:
- Diagnostics and treatment of gastroenterological diseases
- Chronic inflammatory bowel diseases (Crohn's disease, ulcerative colitis, etc.)
- Complex forms of celiac disease (spru)
- Complex forms of pancreatic diseases
- Rare immunologically mediated diseases of the digestive tract, biliary tract and pancreas
- Suspected cancers of the digestive tract
- Planning of atypical or complex endoscopic procedures
- Gastrointestinal cancers
- Esophageal cancer
- Stomach cancer
- Bowel cancer
- Bile duct cancer
- Pancreatic cancer
- Other types of gastrointestinal cancer
- Neuroendocrine tumors
- Diagnostics and treatment of hematological diseases
- Benign diseases
- Different types of anemia
- Platelet count reduction (thrombocytopenia)
- Neutropenia
- Accumulation diseases (disorders of iron (hemochromatosis) or copper metabolism (Wilson's disease))
- Malignant diseases
- Acute leukemia (acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL))
- Chronic leukemia (chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML))
- Malignant lymphomas
- Multiple myeloma / plasmacytoma
- Myelodysplastic syndrome
- Myeloproliferative diseases (chronic myeloid leukemia (CML), polycythemia vera (PT), idiopathic myelofibrosis (IMF), essential thrombocythemia (ET), etc.)
- Benign diseases
- Diagnostics and treatment of diseases of the liver, bile ducts (hepatology)
- Bile duct diseases
- Chronic liver disease
- Liver transplantation
- Liver tumors
- Special diagnostics of liver disease
- Diagnostics and treatment of infectious diseases
- Chronic viral hepatitis (hepatitis B, C, D)
- Other inflammatory liver diseases
- Liver cirrhosis of various etiologies
- HIV infection
- Opportunistic infections
- Diagnostics and treatment of rheumatic and immunological diseases
- Rheumatoid arthritis
- Inflammatory rheumatic diseases of the joints and spine (spondyloarthritis)
- Collagenoses
- Vasculitides
- Immune deficiency syndromes
- Other diagnostic and therapeutic options
The patients of the department are provided with comprehensive, interdisciplinary treatment. Along with current conventional methods, in certain cases, doctors also use innovative methods as part of the clinical trials. In the treatment of oncological diseases, there is maintained active cooperation with the Comprehensive Cancer Center Meinfranken. In general, the specialists of the department are proud of the opportunity to offer the very latest achievements of medicine and are constantly working to further improve the treatment methods and schemes.
Curriculum vitae
Education and Professional Experience
- 1977 - 1980 Study of Medicine at Eberhard Karls University of Tuebingen.
- 1980 - 1981 DAAD Foundation Fellow, Owen University of Manchester.
- 1982 Guy’s Hospital London.
- 1984 Examination for a medical certificate (Tuebingen).
- 1984 Admission to medical practice.
- 1986 PhD thesis defense, Toxicology Institute Tuebingen (summa cum laude).
- 1986 Scientific Internship at the Max Planck Institute, Martinsried.
- 1984 - 1993 Assistant Physician, Department of Internal Medicine II at the University Hospital Tuebingen.
- 1991 Certified as a General Practitioner.
- 1992 Research internship at the Fred Hutchinson Cancer Research Center (FHCRC), Seattle.
- 1993 Senior Physician at the Department of Hematology, Oncology, Rheumatology and Immunology at the University Hospital Tuebingen.
- 1996 Additional qualification in Hematology and Oncology.
- 1999 Appointed as an Extraordinary Professor, University of Tuebingen.
- 2000 Visiting Professor, City of Hope Hospital, Duarte, USA.
- 2001 Head of the Department, University of Tuebingen.
- 2003 Visiting Professor, City of Hope Hospital, Duarte, USA.
- 20004 Head of the Department of Internal Medicine, Julius Maximilian University of Würzburg.
- 2008 Invitation to the position of the Head of the Department of Internal Medicine III at the Johannes Gutenberg University Mainz (rejection).
- 2011 - 2015 Deputy Dean of the Faculty of Medicine, Julius Maximilian University of Würzburg.
- Since 2015 Vice President of the Julius Maximilian University of Würzburg.
Awards
- 2003 Van Bekkum Award.
- 2011 Honorary Fellow of the Royal College of Pathologists (London).
- 2012 Nobel Lecture, Nobel Committee of the Karolinska Institute.
- Since 2014 Member of the Academy of Science and Literature, Mainz.
Positions in Scientific Societies and Institutions
- Since 1994 Leadership of the German Multiple Myeloma Research Group (DSMM).
- Board Member of the European Network on Multiple Myeloma.
- Since 2004 Head of the Working Group on Maintenance Therapy in the European Network of Competent Healthcare Institutions (EuroNet Leukemia).
- Since 2011 Member of the Management of the Research Group on Indolent Lymphomas (StiL).
- Since 2012 Board Member of the German Network of Healthcare Facilities for Malignant Lymphomas.
- 2013 - 2016 Member of the European Commission Consortium of the Research Project "T-Control".
- Since 2013 Member of the Scientific Council of the Wilhelm Sander Foundation.
- Since 2013 Co-Speaker of the Research Network of the Joint Research Center / Transregio 124 (Pathogenic fungi and human carrier organism) of the German Research Foundation.
- Since 2015 Member of the Scientific Council of the Medical Faculty of the Friedrich Schiller University Jena.
- Since 2018 Co-Speaker of the Research Network of the Joint Research Center / Transregio 221 of the German Research Foundation.
Publications:
- Patriarca F, Bruno B, Einsele H, Spina F, Giaccone L, Montefusco V, Isola M, Nozzoli C, Nozza A, Morabito F, Corradini P, Fanin R. Long-Term Follow-Up of a „Donor“ Versus „No Donor“ Comparison in Multiple Myeloma Patients at First Relapse after Failing Autologous Transplantation. Biol Blood Marrow Transplant. 2017 Oct 12.
- Einsele H, Engelhardt M, Tapprich C, Müller J, Liebisch P, Langer C, Kropff M, Mügge LO, Jung W, Wolf HH, Metzner B, Hart C, Gramatzki M, Hertenstein B, Pfreundschuh M, Rösler W, Fischer T, Maschmeyer G, Kanz L, Hess G, Jäger E, Bentz M, Dürk HA, Salwender H, Hebart H, Straka C, Knop S.Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. Br J Haematol. 2017 Sep 29.
- Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU, Stölzel F, Middeke JM, Röllig C, Taube F, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J Allogeneic Hematopoietic Cell Transplantation in Intermediate Risk Acute Myeloid Leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA Mutations. Study Alliance Leukemia (SAL). Ann Oncol. 2017 Sep 1.
- Richardson P, Roy A, Acharyya S, Panneerselvam A, Mendelson E, Günther A, Lonial S, Einsele H. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. Expert Rev Hematol. 2017 Oct; 10.
- Tsamadou C, Fürst D, Vucinic V, Bunjes D, Neuchel C, Mytilineos D, Gramatzki M, Arnold R, Wagner EM, Einsele H, Müller C, Schrezenmeier H, Mytilineos J. HLA-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients. Haematologica. 2017 Sep 7.
- Hefter M, Lother J, Weiß E, Schmitt AL, Fliesser M, Einsele H, Loeffler J. Human primary myeloid dendritic cells interact with the opportunistic fungal pathogen Aspergillus fumigatus via the C-type lectin receptor Dectin-1. Med Mycol. 2017 Jul 1.
- Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, Karthaus M, Link H, Mahlberg R, Neumann S, Ostermann H, Penack O, Ruhnke M, Sandherr M, Schiel X, Vehreschild JJ, Weissinger F, Maschmeyer G. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2017 Nov Wurster S, Weis P, Page L, Helm J, Lazariotou M, Einsele H, Ullmann AJ. ntra- and inter-individual variability of Aspergillus fumigatus reactive T-cell frequencies in healthy volunteers in dependency of mould exposure in residential and working environment. Mycoses. 2017 Oct.
- Wurster S, Thielen V, Weis P, Walther P, Elias J, Waaga-Gasser AM, Dragan M, Dandekar T, Einsele H, Löffler J, Ullmann AJ. Mucorales spores induce a proinflammatory cytokine response in human mononuclear phagocytes and harbor no rodlet hydrophobins. Virulence. 2017 Aug 7.
- Ziegler S, Weiss E, Schmitt AL, Schlegel J, Burgert A, Terpitz U, Sauer M, Moretta L, Sivori S, Leonhardt I, Kurzai O, Einsele H, Loeffler J. CD56 Is a Pathogen Recognition Receptor on Human Natural Killer Cells. Sci Rep. 2017 Jul 21.
- San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Richardson PG. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. Br J Haematol. 2017 Jun 27.
- Went M, Sud A, Law PJ, Johnson DC, Weinhold N, Försti A, van Duin M, Mitchell JS, Chen B, Kuiper R, Stephens OW, Bertsch U, Campo C, Einsele H, Gregory WM, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Lenive O, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Langer C, Hansson M, Kaiser M, Sonneveld P, Goldschmidt H, Hemminki K, Nilsson B, Morgan GJ, Houlston RS. Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood Cancer J. 2017 Jun 16.
- Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017 May 24.
- Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lückerath K, Schottelius M, Kircher M, Werner RA, Schreder M, Samnick S, Kropf S, Knop S, Buck AK, Einsele H, Wester HJ, Kortüm KM. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. Theranostics. 2017 Apr 8;7(6):1589-1597.
- Fuji S, Einsele H, Kapp M. Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options. Curr Opin Infect Dis. 2017 Aug;30(4):372-376.
- Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol. 2017 May 9.
- García-Guerrero E, Gogishvili T, Danhof S, Schreder M, Pallaud C, Pérez-Simón JA, Einsele H, Hudecek M. Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood. 2017 Jun 22;129(25):3386-3388.
- Lapa C, Schreder M, Lückerath K, Samnick S, Rudelius M, Buck AK, Kortüm KM, Einsele H, Rosenwald A, Knop S. [11 C]Methionine emerges as a new biomarker for tracking active myeloma lesions. Br J Haematol. 2017 May 3. doi: 10.1111/ bjh.14696.
- Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Apr 27.
- Etc.
Photo of the doctor: (c) Universitätsklinikum Würzburg
About hospital
According to the FOCUS magazine in 2019, the University Hospital Würzburg ranks among the top national German hospitals!
The hospital is one of the oldest medical facilities in Germany. The centuries-old traditions of first-class treatment are combined with the very latest achievements of modern evidence-based medicine and advanced expert experience. The hospital is the maximum care medical center and covers all fields of modern medicine. The hospital has an impeccable international reputation and treats a large number of patients from other countries every year.
A distinctive peculiarity of the hospital is active interdisciplinary cooperation. A large number of diseases are diagnosed and treated within the specialized centers, which medical teams rely on the unique experience of treatment of a wide variety of clinical cases. For example, such centers include the General Cancer Center, the Stem Cell Therapy Center, the Breast Health Center, the Gastrointestinal Center, the Thoracic Surgery Center, etc. In total, the hospital has more than 40 centers of this kind. Therefore, the patients of the hospital are confident that they will be offered the most relevant treatment in accordance with the very latest medical recommendations.
In addition to the most advanced achievements and methods of modern medicine, the medical team of the hospital makes every effort to create a comfortable, friendly atmosphere, which promotes patient well-being and recovery.
Photo: (с) depositphotos
Accommodation in hospital
Patients rooms
The patients of the University Hospital Würzburg live in comfortable rooms made in a modern design and bright colors. The patient room includes a bed with a remote control, a bedside table with a sliding table, a wardrobe, a TV. The patient rooms have the possibility of Internet connection. The enhanced-comfort rooms are equipped with a safe, a fridge and upholstered furniture.
Meals and Menus
The patients of the hospital are offered a varied and tasty three meals a day. There is a daily choice of several menus, including a dietary one. In case of intolerance to any food, please inform the medical staff about your food preferences in advance. After that, you will be offered an individual menu. Also, the hospital houses the cafes and cafeterias with a wide assortment of drinks, fresh pastries, fresh salads, sweets and other dishes.
Further details
Standard rooms include:
Toilet
Shower
Wi-Fi
TV
Religion
Christian priests are available for the patients at any time. Representatives of other religions may be requested at any time.
Accompanying person
Your companion may stay with you in your room or at a hotel of your choice during the fixed program.
Hotel
You may stay at the clinic hotel or a hotel of your choice during the outpatient program. Our manager will help you choose the best option.
